GLPwatch
Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis.
Acta Biomed · 2011
Last updated 2026-05-28A 65-year-old woman with type 2 diabetes and cryptogenic cirrhosis was treated with liraglutide. Her blood sugar control improved, and her clinical condition related to the cirrhosis also showed improvement.
AI summary of the abstract below.
| Journal | Acta Biomed, 2011 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.15 |
| NIH percentile | 10 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
In this work Author presents a case report of a female patient of 65 years old who had suffered from type 2 diabetes mellitus and from concomitant cryptogenic cirrhosis. She was treated with liraglutide, an analogue of human GLP-1, obtaining an optimal metabolic control associated with an improved clinical condition for the cirrhosis.
Verbatim abstract via PubMed 22480072 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.